

**APC anti-human TCR V $\alpha$ 24-J $\alpha$ 18 (iNKT cell)**

**Catalog # / Size:** 2314535 / 25 tests  
2314540 / 100 tests

**Clone:** 6B11


**Isotype:** Mouse IgG1,  $\kappa$

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Concentration:** Lot-specific



Human peripheral blood lymphocytes stained with 6B11 APC (lower panel) or APC mouse IgG1 isotype control (upper panel) and CD3 (UCHT1) PE


**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microl to 5 microl per test.** Please check your vial or your CoA to find the suggested use of this reagent to find the suggested use of this reagent per million cells in 100 microl staining volume or per 100 microl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** The 6B11 antibody recognizes the invariant CDR3 region of TCR V $\alpha$ 24-J $\alpha$ Q.

**Application References:** 1. Rout N, *et al.* 2010. *PLoS One* 5:e9787. (FC)



**Description:** Encoded by the TCR V $\alpha$ 24-J $\alpha$ 18 germline configuration, V $\alpha$ 24-J $\alpha$ Q is expressed on a subset of NKT cells, namely invariant NKT (iNKT). V $\alpha$ 24-J $\alpha$ Q TCR interacts with the glycolipid loaded MHC class 1b molecule CD1d, inducing activation and subsequent cytokine production. iNKT cells have been implicated in immune regulation, tumor surveillance, and host response to pathogens. While iNKT cells occur at low frequency in the blood, assorted chemokines contribute to their tissue homing potential.

**Antigen References:** 1. Thomas SY, *et al.* 2003. *J. Immunol.* 171:2571.  
2. Exley MA, *et al.* 2008. *Eur. J. Immunol.* 38:1756.  
3. Montoya CJ, *et al.* 2007. *Immunology.* 122:1.  
4. Gansuud B, *et al.* 2003.

